Pluri Inc.

Director's Dealing • Feb 15, 2022

FORM 4

may continue. See Instruction 1(b).

Section 16. Form 4 or Form 5 obligations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response

1. N nd Ad dre am e a ss Ab mi Za erm an	* of R rtin Pe epo g rso n		2. Iss Na d T ick r T rad ing Sy mb ol uer me an er o PL UR IST EM TH ER AP EU TI CS IN C [ PS TI ]	5. R ela tion shi f R rtin Pe n(s ) to Iss p o epo g rso uer ( Ch eck all lica ble ) ap p
				X	Dir ect or	10% Ow ner
(La st)	(Fir st)	(Mi ddl e)	3. D of Ea rlie st T tion ( Mo nth /Da /Ye ar) ate ran sac y		Off ice r (g ive titl e b elo w)	Oth (sp eci fy bel ) er ow
MA TA M PA RK BU IL DI NG #5 ,			02 /10 /20 22
(Str ) eet			4. If A ndm ent , D ate of Ori ina l Fi led ( Mo nth /Da /Ye ar) me g y	6. Ind ivid	ual Jo int/ Gro Fili ( Ch eck Ap or up ng p	lica ble Lin e)
HA IFA	L3	35 08 40 9		X	For m f iled by On e R rtin Pe epo g rso	n
(Cit y)	(Sta te)	(Zip )			For m f iled by Mo re t han On e R rtin Pe epo g rso n

Ta b le I – N -D iva ive Se rit ies A ire d, Di d o f, o r B fic ia lly Ow d t on er cu cq u sp os e en e ne
1. T itle of S rity (Ins tr. 3 ) ecu	2. T tion Da te ran sac (Mo nth/ Day /Ye ar)	2A. De ed em Exe cut ion Dat e, if any (Mo nth/ Day /Ye ar)	3. T tion ran sac Cod e (I nst r. 8 )		4. S ritie s A ired (A) Dis ecu cqu or (Ins tr. 3 , 4 and 5)		ed Of (D) pos	5. A unt of S ritie mo ecu s Ben efic ially Ow ned Fol low ing Rep orte d	6. O rsh ip F wne orm : Dire ct ( D) o r In dire ct (I) ( Inst r. 4 )	7. N atu f re o Ind irec t Ben efic ial
			Cod e	V	Am t oun	(A) or ( D)	Pric e	Tra ctio n(s ) (In 3 str. nsa and 4)		Ow ship ner (Ins tr. 4 )
Co St ock mm on	02 /10 /20 22		P		80 61 6 ,	A	(1) \$ 1.8	91 75 6 ,	I	By R ose Hi h L td. tec
ock Co St mm on								1, 49 3, 97 3	D

Ta b le II – D iva ive Se rit ies A ire d, Di d o f, o r B fic ia lly Ow d t er cu cq u sp os e en e ne ( uts lls nts t ion ert ib le rit ies ) e.g ., p , c a ar ra , o p s, co nv se cu , w
1. T itle of D eriv ativ e S rity (Ins tr. 3 ) ecu	2. 3. T tion 3A. De ed 4. T ran sac em ran sac Con sion Dat Exe cut ion Dat e, if Cod e (I nstr ver e or E cise (Mo nth/ Day /Ye ar) xer any Pric f (Mo nth/ Day /Ye ar) e o Der ivat ive Sec urit y		tion . 8)	5. N ber of um Der ivat ive Sec urit ies Acq uire d (A ) or Dis ed of ( D) pos (Ins tr. 3 , 4 and 5)		6. D Ex isab le ate erc and Ex pira tion Da te (Mo nth/ Day /Ye ar)		7. T itle and Am t of Se ities oun cur Und erly ing Der ivat ive Sec urit y (I nst r. 3 and 4)		8. P rice of Der ivat ive Sec urit y (Ins tr. 5 )	9. N ber of um Der ivat ive Sec urit ies Ben efic ially Ow ned Fol low ing Rep orte d	10. Ow ship ner For m: Dire ct ( D) or I ndir ect (I) ( Inst r. 4 )	11. Nat of ure Ind irec t Ben efic ial Ow ship ner (Ins tr. 4 )
				Cod e	V	(A)	(D)	Dat e Exe rcis able	Exp irat ion Dat e	Titl e	Am t or oun of Num ber Sha res		n(s ) Tra ctio nsa (Ins tr. 4 )

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the Tel Aviv Stock Exchange in New Israeli Shekels (NIS), at per share purchase prices ranging from NIS 5.70 to NIS 5.90, inclusive, or ranging from \$1.77 to \$1.82 in U.S. Dollars, inclusive (based on an exchange rate of NIS 3.221 per U.S. dollar). The Reporting Person undertakes to provide to Pluristem Therapeutics Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Remarks:

/s/ Zami Aberman

02/14/2022

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.